The Oscars may have come and gone, but the American Institute of Chemical Engineers (AIChE) is readying the red carpet for its annual Pharmaceutical QbD Awards.
QbD (Quality by Design), coined by J.M. Juran and brought to pharma by the FDA, encapsulates best development principles that allow for consistently high product quality, despite variability in process variables and raw materials.
These awards are presented annually to professionals whose work is furthering the goals of the QbD initiative within the worldwide pharmaceutical industry, and to recognize excellence in QbD process development and scale-up. Criteria for selection include contributions to the state of the art in the public domain -- for example, thought leadership presentations, articles, publications, and the sharing of best-practices.
As AIChE awards chair Robert Yule, team leader at GlaxoSmithKline (Research Triangle Park, N.C.) explains, nominees may be working in industry, academia, regulatory, or other relevant working environment, and be from any nation, working at any location. There are no age or experience limits. Preference is given to work that features chemical engineering.
In 2013, AIChE’s newest forum, Pharmaceutical Discovery, Development, and Manufacturing Forum (PD2M) will carry on the tradition by coordinating the nomination and selection process for the QbD awards. There are three awards including:
Outstanding Contribution to QbD for Drug Substance, sponsored by Scale-up Systems
Outstanding Contribution to QbD for Drug Product, sponsored by Pfizer
Excellence in Integrated QbD Practice, sponsored by Merck
Each award includes $1,500 and a commemorative plaque, which will be presented at a special awards ceremony dinner during AIChE’s annual meeting, November 3-6, in San Francisco. More information about the annual meeting can be accessed here.
Past award winners were respected individuals well known for their work to advance QbD:
2010 -- Kevin Seibert (Eli Lilly) and Sal Garcia-Munoz (Pfizer)
2011 -- Jose Tabora (BMS), Steve Hammond (Pfizer), and Theodora Kourti (GSK)
2012 -- John Lepore (Merck), Christine Moore (FDA), and Steve Jeffrey (Eli Lilly)
The nomination period for the 2013 awards will close June 15, 2013. After the nomination period has closed, the PD2M QbD Awards Chair compiles the nominations and coordinates the award voting via a blind judging panel consisting of senior members of the AIChE PD2M Forum. The blind judging system was established so that award sponsors cannot influence to whom the award is given. Questions regarding the QbD Awards should be directed to Bob Yule of GSK at Robert.E.Yule@GSK.com.
Look for a quiz on QbD, and blog posts on the topic, here next week.
even better I'd like to see a QbD award based on actual quality improvements leading to safer products or a more profitable enterprise -- not on publicity generated. But how to achieve this? I suspect the quietest organizations are achieving the most, foregoing the publicity in favor of results.
Nominate Your Peers for Excellence in QbD With some AIChE awards going back decades, it's great to see top-level professional acknowledgments in this much more recent – and incredibly important – field. Pity the Institute doesn't make it a tiny bit easier to learn the lessons from past winners.